The FDA’s Commissioner’s National Priority Voucher (CNPV) Pilot Program, launched in June 2025, creates a highly accelerated 1–2 month review pathway for products addressing key national health priorities such as unmet medical needs, domestic manufacturing resiliency, public health threats, healthcare affordability, and advanced therapeutic innovation. Entry into the program may occur through FDA nomination or a brief sponsor- submitted application.
White Paper
Commissioner’s National Priority Voucher (CNPV) Pilot Program
Related Resources
All Resources
post
Why Protocol Amendments Matter: A Clinical Regulatory Medical Writing Perspective
Read More
post
Understanding FDA’s Real-Time Oncology Review (RTOR Medical Abbreviation) Program
Read More
white-paper
FDA CRLs Reveal a Pattern: Biologic Control Strategy Issues Drive Delays and Rejections
Read More
post
When the Only Drug Runs Out: Lessons from the Bicillin® L-A Recall
Read More
Let's move from science to success.
Let’s Talk